Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system
HIV Medicine · 2026
DOI: 10.1111/hiv.70205 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von Leidan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beiji…. Hauptthemen laut MEDLINE: Weight Gain, HIV Infections, HIV Integrase Inhibitors, Pharmacovigilance. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital, the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences, National Key Technologies R&D Program for the 13th Five-year Plan.
Themen: Patientensicherheit
Abstract (Originalsprache)
Objective
Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged. This study aimed to evaluate the association between INSTIs and metabolic adverse events (AEs), including weight gain and glucose/lipid disorders.
Design
The US Food and Drug Administration Adverse Event Reporting System (FAERS) reports from the first quarter (Q1) of 2004 through Q1 2025 were analysed for AEs associated with bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL), focusing on weight gain and glucose/lipid metabolism disorders. Kaplan–Meier curves and Weibull shape parameter tests were used to analyse the cumulative incidence and time to onset of AEs.
Results
All four INSTIs were associated with safety signals for weight gain and glucose/lipid metabolism disorders. BIC had the highest reporting odds ratio (ROR) for weight gain (ROR: 7.70, 95% CI: 7.00–8.47), while DTG had the highest for glucose/lipid disorders (1.81, 95% CI: 1.66–1.97). Younger age and female sex were linked to BIC‐related weight gain; older age was a risk factor for DTG‐, EVG‐ and RAL‐related glucose/lipid AEs. DTG‐associated events occurred earlier than those with other agents.
Conclusion
This study identified metabolic AEs associated with INSTIs, with agent‐specific differences in risk and timing, highlighting the need for regular monitoring and individualized management during INSTI‐based ART.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- School of Medicine, Tsinghua University, Beijing, China.
- State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
ORCID-Profile: Xin Huang
Förderung
- the Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital
- the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
- National Key Technologies R&D Program for the 13th Five-year Plan
- Chinese Academy of Medical Sciences
Zitieren
APA
Zhang, L., Chen, L., Tang, J., Liu, X., Zheng, L., Wang, F., Huang, X., Cao, W., & Li, T. (2026). Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. HIV Medicine. https://doi.org/10.1111/hiv.70205
Vancouver
Zhang L, Chen L, Tang J, Liu X, Zheng L, Wang F, et al. Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. HIV Medicine. 2026. doi:10.1111/hiv.70205
BibTeX
@article{Zhang2026,
author = {Zhang, Leidan and Chen, Ling and Tang, Jia and Liu, Xiaosheng and Zheng, Liyuan and Wang, Fada and Huang, Xin and Cao, Wei and Li, Taisheng},
title = {Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70205}
}
EUVIMED